Sort   by:  
 Page size 
UnknownSARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandem...
S-EPMC8723827 | biostudies-literature
UnknownMortality results from a randomized prostate-cancer screening trial.

Background

The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mort...
S-EPMC2944770 | biostudies-literature
UnknownGlobal overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study).

Background

This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic.

Methods

CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute c...
S-EPMC9071082 | biostudies-literature
UnknownColorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Background

The benefits of endoscopic testing for colorectal-cancer screening are uncertain. We evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence and mortality.

Methods

From 1993 through 2001, we randomly assigned 154,900 men and women 55 to ...
S-EPMC3641846 | biostudies-literature
UnknownUse of Telemedicine for Postdischarge Assessment of the Surgical Wound: International Cohort Study, and Systematic Review With Meta-analysis.

Objective

This study aimed to determine whether remote wound reviews using telemedicine can be safely upscaled, and if standardized assessment tools are needed.

Background

Surgical site infection (SSI) is the most common complication of surgery worldwide, and frequently occurs after h...
S-EPMC10174106 | biostudies-literature
UnknownSurgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study.

Background

Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world.

Methods...

S-EPMC5910057 | biostudies-literature
UnknownSurgical site infection after gastrointestinal surgery in children: an international, multicentre, prospective cohort study.

Introduction

Surgical site infection (SSI) is one of the most common healthcare-associated infections (HAIs). However, there is a lack of data available about SSI in children worldwide, especially from low-income and middle-income countries. This study aimed to estimate the incidence of SSI ...
S-EPMC7716674 | biostudies-literature
UnknownGlobal variation in anastomosis and end colostomy formation following left-sided colorectal resection.

Background

End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection.

Metho...

S-EPMC6921967 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination o...
S-EPMC11872607 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.

Methods

In the randomised, cont...
S-EPMC10957483 | biostudies-literature
Sort   by:  
 Page size